Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 9/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | HTR2B | P41595 | 5/20 | 0.34 |
| ▸ | HTR2C | P28335 | 4/20 | 0.32 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.31 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.31 |
| ▸ | TSPO | P30536 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6166421 | 0.78 | CRHR1 (0.49) | CRHR1 | |
| SCHEMBL6345411 | 0.76 | TP53 (0.37) | CRHR1 | |
| SCHEMBL6350199 | 0.76 | TP53 (0.37) | CRHR1 | |
| SCHEMBL6166430 | 0.75 | CRHR1 (0.38) | CRHR1 | |
| SCHEMBL6167497 | 0.74 | TLR8 (0.40) | CRHR1 | |
| SCHEMBL6166412 | 0.74 | KMT2A (0.43) | ADORA3 | |
| SCHEMBL6168054 | 0.73 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL6168593 | 0.73 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL6167603 | 0.73 | CRHR1 (0.42) | CRHR1 | |
| SCHEMBL6165519 | 0.72 | CRHR1 (0.51) | CRHR1NISCHADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6964965-B2 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1499599-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040053941-A1 | Substituted pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003091225-A1 | SUBSTITUTED PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053941-A1 | Substituted pyrazine derivatives | CRHR1, CRHR2, CRH | CRHR1 1/4885NISCH 1843/4885ADORA1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.